The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect
Abstract
Increasing the complexity of their models, p53s are stabilized either in order to func‐tion (wt p53) or due to the loss of function (mutant p53) with acquiring a mysterious prion‐like ability to drive the normal p53 into the abnormal conforma‐tion to gain new functions. As already recognized, the loss of trans‐activating function leads to a stabi‐lization of mutant p53 because of the disappearance of the p53‐inducible proteins, which otherwise di‐rectly (Mdm‐2) or indirectly (p21) target p53 for degradation. Simplifying further, I will discuss that the loss of function results in a dominant‐negative effect and gain‐of‐function (a dominant‐positive ef‐fect). Thus, mutant p53 lacking trans‐activation func‐tion nevertheless may retain the ability to repress transcription due to its competition with numerous transcription factors for their coactivators. When mutant p53 competes with wt p53, the inhibition of the wt p53‐dependent transcription is perceived as a dominant‐negative effect. Just like trans‐repression, a dominant‐negative effect requires an excess of p53 and, therefore, a ‘dominant’‐negative effect is not dominant. Furthermore, the stabilization of an en‐dogenous mt p53 due to the loss of wt functions cannot occur in the presence of the wt p53 allele. Given the inability of mutant p53 to accumulate in the presence of wt p53, a dominant‐negative effect does not naturally occur and, not surprisingly, het‐erozygous mt/wt cells are rare. The detection of a dominant‐negative effect simply indicates that mu‐tant p53 indeed has lost its function. Last, since mutant p53 loses some or most but not all activities and accumulates in the absence of wt allele, gain‐of‐function can be considered as an exaggeration of the remaining functions. Applications to cancer therapy are discussed.—Blagosklonny, M. V. p53 from complexity to simplicity: mutant p53 stabilization, gainof‐function, and dominant‐negative effect. FASEB J. 14, 1901–1907 (2000)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1×
“Since loss of p53 increase rate of mutations or genomic instability ( 70 ), one can envision that wt p53 may provide advantages in certain conditions.”
BackgroundTumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Mdm-2, which in turn targets p53 for degradation (22, 23).”
BackgroundKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“degradation because the Mdm-2 knockout is lethal and is corrected by the p53 knockout (33).”
BackgroundA Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
DNA damage induces phosphorylation of the amino terminus of p53
Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997) · Genes & Development · doi:10.1101/gad.11.24.3471 · Cited by 818
Cited by
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
Hui, L., Zheng, Y., Yan, Y., Bargonetti, J., & Foster, D. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209735 · Cited by 218
Tong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86
Retracted
Metadata
- Authors
- Blagosklonny, M. V.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2000-10
- Volume
- 14
- Issue
- 13
- Pages
- 1901-1907
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2042848097
- Cited by
- 170
- References
- 11
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect. https://app.cochat.ai/papers/10.1096/fj.99-1078rev
- The paper
- Blagosklonny, M. V. (2000). p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect. The FASEB Journal. https://doi.org/10.1096/fj.99-1078rev
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.